http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2020274312-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f4a900d2d9308385d00e4c55a0114bd |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 |
| filingDate | 2020-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13fd00f1cd1690d0f5c1b722bc67bf3b |
| publicationDate | 2021-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2020274312-A1 |
| titleOfInvention | Method of improving lower urinary tract symptoms |
| abstract | The embodiments include methods of improving the symptoms of mammals having LUTS, using compositions containing Fexapotide Triflutate and a pharmaceutically acceptable carrier. The method includes, but is not limited to, administering Fexapotide Triflutate intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or with a carrier to a mammal in need thereof. |
| priorityDate | 2019-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.